Clinical Outcomes in Patients Undergoing Triple-Vessel Angioplasty for Symptomatic Coronary Artery Disease


Current treatment strategies for multi-vessel coronary artery disease include either coronary artery bypass surgery or percutaneous coronary intervention with stenting. The present study evaluates the morbidity and mortality among coronary artery disease patients undergoing triple-vessel angioplasty. This prospective record based descriptive study was carried out in Medical College, Pariyaram, Kannur, Kerala; a tertiary care cardiac centre in South India. Fifty consecutive patients who underwent angioplasty of one or more lesions in each of the three major coronary arteries from May 2010 to July 2012 were included in the study. The study describes the clinical profile of the patients and a moderate term clinical follow-up to reassess the symptoms, functional status and left ventricular function by history, electrocardiogram, echocardiogram, and treadmill test. Mortality and morbidity were considered as end-points of the study. Event-free survival rate was 94% at a mean follow-up of 20 months. Overall 98% continued success was obtained with triple-vessel angioplasty. Triple-vessel angioplasty is a safe and effective therapy as an alternative to surgical revascularization in selected patients with triple-vessel coronary artery disease.

Share and Cite:

Manzil, A. , Rajan, J. and Radhakrishnan, V. (2015) Clinical Outcomes in Patients Undergoing Triple-Vessel Angioplasty for Symptomatic Coronary Artery Disease. International Journal of Clinical Medicine, 6, 746-752. doi: 10.4236/ijcm.2015.610100.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. (2015) Heart Disease and Stroke Statistics-2015 Update: A Report from the American Heart Association. Circulation, 131, e29.
[2] Casey, C. (2004) Multi-Vessel Coronary Disease and Percutaneous Coronary Intervention. Heart, 90, 341-346.
[3] Favaloro, R.G. (1968) Saphenous Vein Autograft Replacement of Severe Segmental Coronary Artery Occlusion: Operative Technique. The Annals of Thoracic Surgery, 5, 334-339.
[4] Grüntzig, A.R., Senning, Å. and Siegenthaler, W.E. (1979) Nonoperative Dilatation of Coronary-Artery Stenosis: Percutaneous Transluminal Coronary Angioplasty. New England Journal of Medicine, 301, 61-68.
[5] Hannan, E.L., Wu, C., Walford, G., Culliford, A.T., Gold, J.P., Smith, C.R., et al. (2008) Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease. New England Journal of Medicine, 358, 331-341.
[6] Indolfi, C., Pavia, M. and Angelillo, I.F. (2005) Drug-Eluting Stents versus Bare Metal Stents in Percutaneous Coronary Interventions (a Meta-Analysis). The American Journal of Cardiology, 95, 1146-1152.
[7] Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O’Shaughnessy, C., et al. (2003) Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. New England Journal of Medicine, 349, 1315-1323.
[8] Holmes, D.R., Leon, M.B., Moses, J.W., Popma, J.J., Cutlip, D., Fitzgerald, P.J., et al. (2004) Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial a Randomized Trial of a Sirolimus-Eluting Stent versus a Standard Stent in Patients at High Risk for Coronary Restenosis. Circulation, 109, 634-640.
[9] Ardissino, D., Cavallini, C., Bramucci, E., Indolfi, C., Marzocchi, A., Manari, A., et al. (2004) Sirolimus-Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary Arteries: A Randomized Trial. JAMA, 292, 2727-2734.
[10] Katritsis, D.G., Karvouni, E. and Ioannidis, J.P. (2005) Meta-Analysis Comparing Drug-Eluting Stents with Bare Metal Stents. The American Journal of Cardiology, 95, 640-643.
[11] Regar, E., Serruys, P., Bode, C., Holubarsch, C., Guermonprez, J., Wijns, W., et al. (2002) Angiographic Findings of the Multicenter Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size. Circulation, 106, 1949-1956.
[12] Morice, M.-C., Serruys, P.W., Sousa, J.E., Fajadet, J., Ban Hayashi, E., Perin, M., et al. (2002) A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. New England Journal of Medicine, 346, 1773-1780.
[13] Mohr, F.W., Morice, M.-C., Kappetein, A.P., Feldman, T.E., Ståhle, E., Colombo, A., et al. (2013) Coronary Artery Bypass Graft Surgery versus Percutaneous Coronary Intervention in Patients with Three-Vessel Disease and Left Main Coronary Disease: 5-Year Follow-Up of the Randomised, Clinical SYNTAX Trial. The Lancet, 381, 629-638.
[14] Panchal, K., Patel, S. and Bhatt, P. (2012) Drug-Eluting Stents in Multivessel Coronary Artery Disease: Cost Effectiveness and Clinical Outcomes. Advances in Pharmacological Sciences, 2012, Article ID: 679013.
[15] Hoffman, S.N., TenBrook, J.A., Wolf, M.P., Pauker, S.G., Salem, D.N. and Wong, J.B. (2003) A Meta-Analysis of Randomized Controlled Trials Comparing Coronary Artery Bypass Graft with Percutaneous Transluminal Coronary Angioplasty: One- to Eight-Year Outcomes. Journal of the American College of Cardiology, 41, 1293-1304.
[16] Buszman, P.E., Buszman, P.P., Bochenek, A., Gierlotka, M., Gasior, M., Milewski, K., et al. (2014) Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (From the Milestone Registry). The American Journal of Cardiology, 114, 979-987.
[17] van den Brand, M.J., Rensing, B.J., Marie-Angèle, M.M., Foley, D.P., de Valk, V., Breeman, A., et al. (2002) The Effect of Completeness of Revascularization on Event-Free Survival at One Year in the ARTS Trial. Journal of the American College of Cardiology, 39, 559-564.
[18] Moustapha, A. and Anderson, H.V. (2000) Revascularization Interventions for Ischemic Heart Disease. Current Opinion in Cardiology, 15, 463-471.
[19] Morrison, D. (2005) Multivessel Percuta-neous Coronary Intervention: A New Paradigm for a New Century. Minerva Cardioangiologica, 53, 361-377.
[20] Kim, L.J., King, S.B., Kent, K., Brooks, M.M., Kip, K.E., Abbott, J.D., et al. (2009) Factors Related to the Selection of Surgical versus Percutaneous Revascularization in Diabetic Patients with Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) Trial. JACC: Cardiovascular Interventions, 2, 384-392.
[21] Booth, J., Clayton, T., Pepper, J., Nugara, F., Flather, M., Sigwart, U., et al. (2008) Randomized, Controlled Trial of Coronary Artery Bypass Surgery versus Percutaneous Coronary Intervention in Patients with Multivessel Coronary Artery Disease Six-Year Follow-Up from the Stent or Surgery Trial (SoS). Circulation, 118, 381-388.
[22] Kirtane, A.J., Gupta, A., Iyengar, S., Moses, J.W., Leon, M.B., Applegate, R., et al. (2009) Safety and Efficacy of Drug-Eluting and Bare Metal Stents Comprehensive Meta-Analysis of Randomized Trials and Observational Studies. Circulation, 119, 3198-3206.
[23] Athappan, G., Patvardhan, E., Tuzcu, M.E., Ellis, S., Whitlow, P. and Kapadia, S.R. (2013) Left Main Coronary Artery Stenosis: A Meta-Analysis of Drug-Eluting Stents versus Coronary Artery Bypass Grafting. JACC: Cardiovascular Interventions, 6, 1219-1230.
[24] Daemen, J., Kuck, K.H., Macaya, C., Le Grand, V., Vrolix, M., Carrie, D., et al. (2008) Multivessel Coronary Revascularization in Patients with and without Diabetes Mellitus: 3-Year Follow-Up of the ARTS-II (Arterial Revascularization Therapies Study—Part II) Trial. Journal of the American College of Cardiology, 52, 1957-1967.
[25] Rodriguez, A.E., Grinfeld, L., Fernandez-Pereira, C., Mieres, J., Rodriguez, A.M., Berrocal, D., et al. (2006) Revascularization Strategies of Coronary Multiple Vessel Disease in the Drug Eluting Stent Era: One Year Follow-Up Results of the ERACI III Trial. Euro Intervention: Journal of Euro PCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2, 53-60.
[26] Ong, A.T., Serruys, P.W., Mohr, F.W., Morice, M.-C., Kappetein, A.P., Holmes, D.R., et al. (2006) The SYNergy between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery (SYNTAX) Study: Design, Rationale, and Run-In Phase. American Heart Journal, 151, 1194-1204.
[27] Serruys, P.W., Morice, M.-C., Kappetein, A.P., Colombo, A., Holmes, D.R., Mack, M.J., et al. (2009) Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine, 360, 961-972.
[28] Morice, M.-C., Serruys, P.W., Kappetein, A.P., Feldman, T.E., Ståhle, E., Colombo, A., et al. (2014) Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery Trial. Circulation, 129, 2388-2394.
[29] Kappetein, A.P., Head, S.J., Morice, M.-C., Banning, A.P., Serruys, P.W., Mohr, F.-W., et al. (2013) Treatment of Complex Coronary Artery Disease in Patients with Diabetes: 5-Year Results Comparing Outcomes of Bypass Surgery and Percutaneous Coronary Intervention in the SYNTAX Trial. European Journal of Cardio-Thoracic Surgery, 43, 1006-1013.
[30] Caixeta, A., Généreux, P., Palmerini, T., Lansky, A.J., Mehran, R., Dangas, G.D., et al. (2014) Prognostic Utility of the SYNTAX Score in Patients with Single versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (From the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). The American Journal of Cardiology, 113, 203-210.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.